Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

First Patient Implant of Stroke Treatment Device

August 28, 2013 By MicroTransponder

MicroTransponder, Inc., a privately-held medical device company has several announcements. The Company announced that it completed a $3.39 Million funding round this summer, which will enable the Company to complete 3 additional clinical trials using their neurostimulation system to treat both stroke patients and tinnitus patients and continue development of their wireless pain platform. This round of investment was led by Green Park & Golf Ventures, a Texas based healthcare investment firm. The round also included angel investors and the UT Horizon Fund.

“MicroTransponder’s VNS paired neurostimulation therapy has the potential to fundamentally change the standard of care for neurological disease,” states Dr. Clay Heighten, a founding partner of Green Park & Golf Ventures. “The MicroTransponder team is adept at translating neuroscience research into clinical therapies and we look forward to their efforts to improve the lives of millions of patients living with neurological disorders.”

MicroTransponder is dedicated to rigorous scientific research standards and thus continues to publish academic papers on their neuroscience research in respected peer reviewed academic journals. From this rigorous neuroscience research, a new vagus nerve stimulation therapy has been developed to treat various neurological disorders. The initial therapeutic targets are stroke, tinnitus, and chronic pain.

The Vivistim® System has been developed to treat stroke patients that experience an upper-limb deficit following their stroke. These are patients that are unable to fully recover the use of their upper-limbs at least 6 months following their stroke. A United Kingdom based clinical trial is underway using the Vivistim® System in the Glasgow and Newcastle areas. The first patient has been implanted and is receiving therapy. Anyone currently living in the UK interested in taking part in the study should contact: mvls-armweakness@glasgow.ac.uk or call 0141 211 2948. A U.S. based stroke trial is planned for 2014. Please visit www.MicroTransponder.com to get the latest updates.

The Serenity® System has been developed to treat patients who suffer from tinnitus. Tinnitus is the annoying perception of sound in the ears or head where no external source is present, commonly referred to as “constant ringing in the ears”. The American Tinnitus Association estimates that as many as 2 million Americans currently suffer from severe debilitating tinnitus. 850,000 Veterans currently suffer from tinnitus and the Veterans Administration is spending over $1.5 Billion annually in disability payments.

The Serenity® System is a neurostimulation based system with a small implanted battery and wires that internally connect to the vagus nerve in the neck. As part of the therapy, the patient wears headphones and every time the system plays a tone, it also automatically delivers a small amount of neurostimulation to the patient’s vagus nerve. This paired tone-stimulation treatment method is based on years of neuroscience research published in high impact journals. Tinnitus clinical trials in the U.S. will begin later this year; more details will be announced later in the year on www.MicroTransponder.com

Additionally, MicroTransponder announced the issuance of a U.S. Patent for “Timing Control for Paired Plasticity.” (U.S. Patent # 8,489,185). This patent forms the foundation of the intellectual property portfolio covering the device and paired neurostimulation therapy which can be used to treat a variety of neurological conditions.

This funding and stroke trial announcement is another important milestone for the Company. Frank McEachern, CEO of MicroTransponder, states, “We are committed to bringing this therapy to market. Patients with neurological disease currently have too few treatment options available to them. It is essential to bring neuroscience-based innovation into the clinic.”

For more information, visit www.microtransponder.com.

Related Articles Read More >

A portrait of ResMed President and COO Rob Douglas
ResMed finds a solution to semiconductor shortage, as well as some humor in it
Johnson & Johnson Office of Digital Innovation Leader Peter Schulam
Imagining the future of cloud-connected medical devices with Johnson & Johnson leaders
Withings Body Scan
Withings plans launch for Body Scan smart scale platform
BinaxNow COVID-19 Ag Card
Time recognizes Abbott offerings among this year’s 100 best inventions

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech